Dynavax Technologies Corporation (DVAX)

Dynavax Technologies Corporation (DVAX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NASDAQ.

As of Feb 9, 2026: market cap $1.8B; returns 1 week +0.1%, 1 year +17.9%.

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company primarily focused on developing and commercializing innovative vaccines to prevent infectious diseases. Its core revenue driver is HEPLISAV-B, an adult hepatitis B vaccine approved in the U.S., European Union, and United Kingdom.

DVAX financial model: income statement, cash flow and balance sheet